Apixaban Preoperative Discontinuation Guidelines

Discontinuation Recommendations

For patients with normal renal function, the American College of Chest Physicians recommends holding apixaban for 2 days before low-to-moderate bleeding risk procedures and 3 days before high bleeding risk procedures 1, 2, 3
For low-to-moderate bleeding risk surgery in patients with normal renal function, the last dose of apixaban should be 2 days before surgery, corresponding to 2-3 half-lives 1, 2, 3
For high bleeding risk surgery in patients with normal renal function, the last dose of apixaban should be 3 days before surgery, corresponding to 4-5 half-lives 1, 2, 3

High bleeding risk procedures include cardiac, intracranial, or spinal surgery, surgery in highly vascular organs, and any major operation, according to the American College of Chest Physicians 2, 3
Low-to-moderate bleeding risk procedures include arthroscopy, laparoscopic cholecystectomy, abdominal hernia repair, colonoscopy with biopsy, and coronary angiography, as classified by the American College of Chest Physicians 2, 3

The half-life of apixaban is 7-8 hours in patients with normal renal function, with 27% of total clearance being renal, as reported in the Blood journal 1, 2
The time to minimal anticoagulation is 2-3 half-lives, achieving a mild residual effect, and 4-5 half-lives achieves minimal effect, according to the Blood journal 1, 2

Bridging anticoagulation is not required during the 24-48 hour interruption period due to apixaban's rapid offset and onset of action, as stated in the Chest journal 3
For neuraxial procedures, a longer 3-day discontinuation period is recommended even for patients with normal renal function, due to the risk of epidural hematoma, as advised by the Chest journal and the American College of Chest Physicians 3
Renal function assessment is mandatory before determining the discontinuation timeline, as moderate impairment significantly prolongs apixaban elimination, according to the Blood journal 1, 2

Apixaban should be resumed at least 24 hours after surgery, once adequate hemostasis is established, as recommended by the Chest journal 3
For high bleeding risk procedures, consider resuming apixaban at 2-3 days postoperatively, as suggested by the Chest journal 3

The American College of Cardiology recommends a full 72-hour (3-day) discontinuation period for neuraxaban procedures, such as spinal or epidural anesthesia, in patients with normal renal function, due to the catastrophic risk of epidural hematoma 4
The American College of Cardiology suggests that bridging anticoagulation is NOT required during the 24-72 hour interruption period due to apixaban's rapid offset and onset of action, simplifying perioperative care 4
According to the American College of Cardiology, INR or aPTT should not be used to guide timing, as apixaban's effect on these tests is inconsistent, and they should not be relied upon for surgical clearance 4
The American College of Cardiology advises to avoid procedures with cardiac perforation risk without adequate drug clearance, ensuring complete drug elimination, as no specific reversal agent is readily available for apixaban 4

Stop apixaban 48 hours before hand surgery in patients with normal renal function (creatinine clearance > 50 mL/min), because the procedure is classified as moderate bleeding risk. 5
Do not use bridging anticoagulation with heparin during the interruption; bridging has been shown to increase major bleeding without lowering the risk of stroke or systemic embolism. 5
If renal function is impaired (creatinine clearance 30–50 mL/min), extend the pre‑operative hold to 72 hours to allow for reduced drug clearance. 5

Resume apixaban at least 24 hours after hand surgery once adequate hemostasis is confirmed and there is no active bleeding. 5
The rapid onset of apixaban (peak effect within 3–4 hours) provides prompt anticoagulation, eliminating the need for any bridging therapy after surgery. 5

Do not rely on INR or aPTT to guide the timing of interruption or resumption, because these coagulation tests are inconsistent for measuring apixaban effect. 5

Patients with a history of pulmonary embolism have high thrombotic risk; a short anticoagulation gap of 24–48 hours (pre‑ and post‑operative) is considered acceptable provided that therapy is restarted promptly. 5
The brief interruption (48 hours pre‑op + 24–48 hours post‑op) carries minimal thrombotic risk compared with the substantially higher bleeding risk of continuing apixaban through the surgery. 5